fluorodeoxyglucose

fluorodeoxyglucose is a radiopharmaceutical and glucose analog where a hydroxyl group is replaced by radioactive fluorine-18. It is the foundational tracer for positron emission tomography imaging, a cornerstone of modern nuclear medicine. Its development, particularly at Brookhaven National Laboratory and the University of Pennsylvania, revolutionized oncology, neurology, and cardiology diagnostics by enabling the visualization of metabolic activity.

Chemical properties and synthesis

The molecular structure is nearly identical to glucose, differing by the substitution of the 2-hydroxyl group with the positron-emitting isotope fluorine-18. This structural mimicry is key to its biological behavior. Synthesis is achieved through nucleophilic substitution reactions, typically using a precursor like mannose triflate in automated modules such as the GE TracerLab. The process requires a cyclotron to produce the short-lived fluorine-18, followed by rapid radiochemical synthesis and purification to yield the injectable compound.

Medical applications

Its primary use is in PET/CT scans for cancer staging, assessing treatment response, and detecting recurrence in malignancies like lung cancer, lymphoma, and breast cancer. In neurology, it is critical for evaluating epilepsy foci in pre-surgical planning for conditions like mesial temporal lobe epilepsy, and for differentiating Alzheimer's disease from other dementias such as frontotemporal dementia. In cardiology, it identifies viable myocardium in patients with coronary artery disease being considered for revascularization procedures.

Mechanism of action

After intravenous injection, it is transported into cells via glucose transporter proteins, such as GLUT1. Within the cell, it is phosphorylated by hexokinase to fluorodeoxyglucose-6-phosphate. Unlike normal glucose, this metabolite cannot be further processed by glycolysis or glucose-6-phosphate dehydrogenase, and becomes metabolically trapped intracellularly. Cells with high glycolytic rates, such as aggressive tumor cells or active neurons, accumulate more of the tracer, which is detected as increased radioactivity by the PET scanner.

Production and radiochemistry

Production is a tightly controlled process integrating particle accelerator technology and good manufacturing practice. A cyclotron bombards a oxygen-18 enriched water target with protons to generate fluorine-18 fluoride. This is then used in a hot cell with automated synthesis modules, often based on methods developed at the Johns Hopkins University. Rigorous quality control testing for sterility, apyrogenicity, and radiochemical purity is performed before release. The logistics are challenging due to the 110-minute half-life of fluorine-18, requiring a just-in-time distribution network from production sites like Cardinal Health or IBA Molecular.

Pharmacokinetics and safety

Following injection, it distributes throughout the body, with high physiological uptake in the brain, myocardium, and bladder. Patients are advised to fast beforehand to reduce competitive uptake in skeletal muscle and myocardium. The effective radiation dose is comparable to other diagnostic procedures like CT scans of the abdomen and pelvis. Adverse reactions are exceedingly rare, though precautions are taken for patients with diabetes mellitus due to altered glucose metabolism. Excretion is primarily renal, leading to high activity in the ureters and urinary bladder, which is a consideration for imaging pelvic malignancies.

Category:Radiopharmaceuticals Category:Glucose analogs Category:Diagnostic agents